United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Can Johnson & Johnson’s nipocalimab redefine autoimmune treatment by targeting Sjögren’s disease at its root? Nipocalimab showed major efficacy in Phase 2 Sjögren’s disease trial. Discover how Johnson & Johnson is advancing autoimmune therapies with its FcRn pipeline. bySrinathOctober 25, 2025